Could antitumor activity of curcumin in patients be due to its metabolites? A response

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 7108-7109

  Dhillon, Navneet ^a   Sung, Bokyung ^a   Kurzrock, Razelle ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FERULIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; VANILLIN;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; DRUG BLOOD LEVEL; DRUG DEGRADATION; ENZYME INHIBITION; HUMAN; IN VIVO STUDY; LETTER; PANCREAS CANCER; PRIORITY JOURNAL;

EID: 72549102585     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2362     Document Type: Letter

References (5)

1. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008;14:4491-4499
2. Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997;15:1867-1876
3. Murakami Y, Hirata A, Ito S, et al. Re-evaluation of cyclooxygenase-2- inhibiting activity of vanillin and guaiacol in macrophages stimulated with lipopolysaccharide. Anticancer Res 2007;27:801-807 (Pubitemid 46586984)
4. Jayaprakasam B, Vanisree M, Zhang Y, Dewitt DL, Nair MG. Impact of alkyl esters of caffeic and ferulic acids on tumor cell proliferation, cyclooxygenase enzyme, and lipid peroxidation. J Agric Food Chem 2006;54:5375-5381 (Pubitemid 44195715)
5. Jung KJ, Go EK, Kim JY, Yu BP, Chung HY. Suppression of age-related renal changes in NF-κB and its target gene expression by dietary ferulate. J Nutr Biochem 2009;20:378-388